Healthcare
Guggenheim Securities continues to provide healthcare clients with independent insight and expertise across the biopharma, medical devices, and healthcare services sectors. Our full-service firm includes a leading healthcare investment banking franchise, trusted as a long-term, strategic advisor, as well as sales & trading services and a research department that performs deep primary research and generates actionable ideas.
The Century Project: Living Longer, but Less Healthy
Representative Transactions in Healthcare
Social Media
LinkedIn: Bloomberg
What Top Dealmakers Expect to See This Year in Health-Care M&A
Senior Managing Directors Punit Mehta and David Blais shared their views on the M&A outlook in healthcare with Michelle Davis from Bloomberg News.
.jpg)
LinkedIn: Summit City Health
Guggenheim Congratulates Summit Health-CityMD
Guggenheim Securities, LLC congratulates Summit Health-CityMD, a portfolio company of Warburg Pincus LLC, in connection with its definitive agreement to be acquired by VillageMD, an affiliate of Walgreens Boots Alliance. Guggenheim served as a financial advisor to Summit Health-CityMD on the transaction.
LinkedIn: CNBC Closing Bell: Overtime
Guggenheim’s Seamus Fernandez Offers His Bullish Case for Merck
Biopharmaceutical Analyst Seamus Fernandez provides insight on CNBC Closing Bell: Overtime into his recent report on MRK.
LinkedIn: Immunology and Neurology Conference
Guggenheim Thanks Attendees of Immunology and Neurology Conference
Guggenheim Securities would like to thank the presenters and attendees of this week’s Immunology and Neurology Conference.
LinkedIn: Therapeutics Conference
Guggenheim Thanks Attendees of Therapeutics Conference
Guggenheim Securities would like to thank the participants and attendees of this week’s Therapeutics Conference.
LinkedIn: I&I Spotlight Series
I&I Spotlight Series - Treg-based Therapies
Senior Healthcare Sales Specialist Whitney Wolfe interviews Biotechnology Research Analyst Yatin Suneja, covering the biotechnology sector, on the rapid innovation of Tregs for the treatment of autoimmune diseases and diseases of the nervous system.
.jpg)
LinkedIn: Treg-Based Therapies
I&I Spotlight Series: Treg-Based Therapies
Senior Healthcare Sales Specialist Whitney Wolfe interviews Biotechnology Research Analyst Yatin Suneja, covering the biotechnology sector, on the rapid innovation of Tregs for the treatment of autoimmune diseases and diseases of the nervous system.
LinkedIn: I&I Spotlight Series
Guggenheim Thanks Attendees of I&I Spotlight Series
Thank you to everyone who attended this week’s Guggenheim I&I Spotlight Series on Treg-based Therapies.
LinkedIn: Radiopharmaceutical Day
Guggenheim Thanks Attendees of Radiopharmaceutical Day
Guggenheim would like to thank the participants and attendees of Tuesday's Radiopharmaceutical Day.
LinkedIn: Synthetic Lethality Day
Guggenheim Thanks Attendees of Synthetic Lethality Day
Thank you to everyone that attended Monday's virtual Guggenheim Healthcare Talk for Synthetic Lethality Day.
LinkedIn: Tech-Enabled Care
Tech-Enabled Care Industry Overview
Director of Research Craig Peckham interviews Senior Managing Director Sandy Draper and Vice President Jack Wallace, both Equity Research Analysts covering the Healthcare IT & Services sector, on their views on digital healthcare.
LinkedIn: Genomic Medicines and Rare Disease Day
Guggenheim’s 4th Annual Genomic Medicines and Rare Disease Day
At Guggenheim’s 4th Annual Genomic Medicines and Rare Disease Day, we provided healthcare clients with access to industry leadership in the constantly evolving sector.
LinkedIn: Targeted Protein Degradation Day
Highlights From the Second Guggenheim Targeted Protein Degradation Day
Equity Research Analyst Michael Schmidt, who covers biotech, provides highlights from our Targeted Protein Degradation Day, a part of the Guggenheim Healthcare Talks series, on March 16.
LinkedIn: Oncology Conference
Guggenheim Thanks Oncology Conference Attendees
At this year’s Oncology Conference, we provided clients with direct access to industry leadership teams in a complex and constantly evolving sector.
LinkedIn: Biopharma Perspectives
Guggenheim Securities Healthcare - Biopharma Perspectives
At Guggenheim Securities, LLC we provide biopharmaceutical clients with independent insight and advice. As we survey 2022, we are sharing summaries of some of our most compelling thematic reports from the past year.
To access more information related to Healthcare at Guggenheim Securities, contact GSInfo@guggenheimpartners.com.
Important Notices and Disclosures
The information and materials referenced herein (together, the “materials”) are presented for informational and educational purposes only and should not be considered a recommendation of any particular security, strategy or investment product, as investing advice of any kind, or as offering or providing any investment product or service. The materials are not a product of the research department of Guggenheim Securities, LLC or any of its affiliates’ (“Guggenheim”) and should not be construed as a research report, recommendation or advice, or an offer or solicitation with respect to the purchase or sale of any investment. The materials are not provided in an advisory or fiduciary capacity and may not be relied upon for or in connection with the making of investment decisions. The views expressed herein are solely those of the authors and may differ from the views of other officers, directors, employees or other representatives (as to any person or entity, its “Representatives”) of Guggenheim. The authors’ opinions are subject to change without notice. Sources for the information contained herein are believed to be reliable, but the information is not guaranteed as to, and Guggenheim and its Representatives make no representation or warranty regarding, accuracy or completeness of any information contained herein or otherwise. Guggenheim may have a business relationship with certain issuers mentioned herein, or may otherwise underwrite, hold a position, buy or sell as principal in the securities of any issuer mentioned. Guggenheim may have in the past provided, may currently be providing and may in the future seek to provide investment banking, financial advisory and other services to, and have other material relationships with, the issuers of securities, loans and other financial instruments referred to herein and their affiliates. With respect to any position Guggenheim may hold, Guggenheim may have interests different from or adverse to your interests. No part of these materials may be reproduced in any form, or referred to in any other publication, without express written permission of Guggenheim. The materials have been prepared and submitted as of the relevant dates referenced herein, reflect information available to Guggenheim as of or prior to such dates and are based on economic, capital markets and other conditions as of or prior to such dates. There is neither representation nor warranty as to the current accuracy of, nor liability for, decisions based on these materials and information. Guggenheim assumes no obligation or liability (express or implied) for updating, correcting or otherwise revising the materials. By accepting delivery of this material, each recipient will be deemed to acknowledge and agree to the matters set forth above.
Copyright © 2023 by Guggenheim Securities, LLC, a FINRA registered broker-dealer. All rights reserved.